Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 Sep 21;8:14211. doi: 10.1038/s41598-018-32601-0

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2018

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Characterization of anti-IF mAb and IF-ADC. (a) Specificity of anti-IF IgG. Reactivities of control antibody and anti-IF antibody were estimated against fibrinogen (FNG), soluble fibrin (SF), D-dimer, fibrin degradation product (FDP) and IF by ELISA (n = 3). Anti-IF mAb specifically recognised IF, but did not recognised its zymogen FNG and its degradation products FDP and D-dimer, whereas control mAb did not recognised FNG, IF, FDP and D-dimer. The results are shown as means ± standard deviation (s.d.). Statistical analysis was performed using the Dunnett test. ^‡P < 0.01. (b) Structure of antibody-drug conjugate. MMAE was conjugated to mAb via PLM cleavable linker and self-immolative spacer. (c) Particle size of mAbs and ADCs. The molecular sizes of the ADCs did not change as compared to that of the corresponding antibody. This may implicate that ADCs were not fragmented or aggregated. (d) Chromatography of released MMAE. The peak at a retention time of 11.8 min is the ibuprofen (IS) peak (blue arrow), and the peak at a retention time of 14.7 min indicates MMAE (red arrow). Control- and IF-ADC released MMAE only when PLM was added, but there was virtually no MMAE release in the absence of PLM.